Avatar is a molecular engineering company that is developing novel universal Influenza and RSV subunit vaccines, both representing $ multi-billion market opportunities with mitigated clinical risk. We apply our patented, nano-scale, di-tyrosine (DT) crosslinking technology to lock key viral proteins in the conformation that best elicits protective antibody responses and in so doing, also improve the thermo-stability and shelf life of the resulting vaccine immunogens.
We have demonstrated that our di-tyrosine platform technology is robust and versatile and we are now able to translate this approach to quickly design and generate vaccine candidates with significant commercial potential and with proprietary composition of matter IP. Avatar has a favorable risk/reward profile because we do not perform de novo discovery, but rather engineer solutions to well-characterized problems that are uniquely addressable with our DT conformational locking technology. Read more about Avatar's Team.
Read more about Avatar's History.
Read more about Avatar's Intellectual Property.
We have demonstrated that our di-tyrosine platform technology is robust and versatile and we are now able to translate this approach to quickly design and generate vaccine candidates with significant commercial potential and with proprietary composition of matter IP. Avatar has a favorable risk/reward profile because we do not perform de novo discovery, but rather engineer solutions to well-characterized problems that are uniquely addressable with our DT conformational locking technology. Read more about Avatar's Team.
Read more about Avatar's History.
Read more about Avatar's Intellectual Property.